A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CONCERTO
- Sponsors AstraZeneca
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.
- 07 Nov 2016 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.
- 07 Nov 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Nov 2018.